Sandoz 2026 Sales Rise 5% at CC as Biosimilars Climb 19%; Core-EBITDA Margin Guidance Upgraded to 23.0-23.5%
Sandoz 2026 sales reached USD 8,703 million in the first nine months, up 5% at constant currencies, with biosimilars up 19% and generics down 1%. The company narrowed full-year net-sales growth guidance to 5-6% and upgraded its core-EBITDA margin outlook to 23.0-23.5%.
Novartis Q3 2026 Results: Kisqali and Kesimpta Lift Sales as Novartis Raises Full-Year Core Operating Income Guidance
Novartis Q3 2026 results show net sales of USD 14.5 billion (+4%) and core operating income up 11%. The company raised its full-year core operating income guidance despite a USD 1.9 billion del-desiran impairment.
IQVIA Q3 2026 Results: IQVIA Holdings Reports $4,428 Million Revenue and Raises Full-Year 2026 Guidance
IQVIA Q3 2026 Results show revenue of $4,428 million, adjusted diluted EPS of $3.34, $3.2 billion in R&D Solutions net new bookings and raised full-year 2026 guidance.
Pfizer TALZENNA XTANDI Approval: FDA Clears Combination for an Earlier Metastatic Prostate Cancer Setting
The FDA has expanded the TALZENNA XTANDI approval to men with HRR gene-mutated metastatic androgen pathway modulation-naïve or -sensitive prostate cancer. The decision rests on Phase 3 TALAPRO-3 data showing an estimated 52% reduction in the risk of radiographic progression or death.
Eli Lilly olomorasib ESMO 2026 Data Show Durable First-Line Activity in KRAS G12C-Mutant NSCLC
Lilly olomorasib ESMO 2026 results show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer. The data cover olomorasib with pembrolizumab, with or without chemotherapy. Lilly expects first randomized Phase 3 SUNRAY-01 data in the first half of 2027.
Johnson & Johnson ESMO 2026: JNJ-6143 RIPTAC Debut, RYBREVANT FASPRO and ERLEADA Lead Solid Tumor Slate
Johnson & Johnson will present more than 25 solid tumor abstracts at ESMO 2026, led by the first JNJ-6143 RIPTAC readout in prostate cancer, new RYBREVANT FASPRO head and neck data and ERLEADA PROTEUS findings.
Eli Lilly Sofe-M Plus Bevacizumab Delivers 79% Response Rate in Platinum-Sensitive Ovarian Cancer at ESMO 2026
Lilly Sofe-M, an investigational FRα-targeting antibody-drug conjugate, combined with bevacizumab produced a 79.3% confirmed objective response rate and 100% disease control in platinum-sensitive ovarian cancer in Phase 1 data, to be presented orally at ESMO 2026 in Madrid.
Abbott Q3 2026 Results: Abbott (NYSE: ABT) Posts 14.5% Sales Growth, Reaffirms Full-Year EPS Guidance Midpoint
Abbott Q3 2026 Results show net sales of $13.013 billion, up 14.5% reported and 7.0% comparable, with adjusted EPS of $1.42 and full-year EPS guidance tightened to $5.50 to $5.55.
Charles River FDA Collaboration With Labcorp Targets New Preclinical Methods for Abuse Potential Assessment
Charles River, Labcorp and the FDA have signed a Research Collaboration Agreement to develop sensitive preclinical tools that quantify and rank the abuse potential of new drugs, including abuse-deterrent formulations.
Samsung Biologics Q3 2026 Results: Plant 5 Ramp-Up and Rockville Lift Revenue to KRW 1,490 Billion as 2026 Guidance Rises to 20%
Samsung Biologics Q3 2026 Results show revenue of KRW 1,490 billion and operating profit of KRW 640 billion. Plant 5 ramp-up and the Rockville site contributed, and the company raised its 2026 revenue growth guidance to 20%.